This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Hisamitsu Pharmaceutical Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Hisamitsu Pharmaceutical'in kazancının yıllık 1.7% oranında azalması, yıllık gelirinin ise yıllık 4% oranında artması beklenmektedir. EPS'nin yılda 0.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 4.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

-1.7%

Kazanç büyüme oranı

0.21%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	13.1%
Gelir büyüme oranı	4.0%
Gelecekteki özkaynak getirisi	4.90%
Analist kapsamı	Low
Son güncelleme	25 Apr 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • Jan 06

What Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) 25% Share Price Gain Is Not Telling You

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) shareholders have had their patience rewarded with a 25% share price...

Analiz Makalesi • Jan 05

These 4 Measures Indicate That Hisamitsu Pharmaceutical (TSE:4530) Is Using Debt Safely

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Analiz Makalesi • Dec 18

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its periodic dividend on the...

Analiz Makalesi • Jul 11

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) periodic dividend will be increasing on the 7th of November to...

Analiz Makalesi • Jun 27

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) will increase its dividend on the 7th of November to ¥60.00, which is...

Analiz Makalesi • Apr 18

We Think That There Are Issues Underlying Hisamitsu Pharmaceutical's (TSE:4530) Earnings

Unsurprisingly, Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) stock price was strong on the back of its healthy...

Analiz Makalesi • Mar 07

With EPS Growth And More, Hisamitsu Pharmaceutical (TSE:4530) Makes An Interesting Case

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Analiz Makalesi • Feb 17

Does Hisamitsu Pharmaceutical (TSE:4530) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Analiz Makalesi • Jan 13

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will pay a dividend of ¥45.00 per...

Analiz Makalesi • Dec 30

Hisamitsu Pharmaceutical (TSE:4530) Is Due To Pay A Dividend Of ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will pay a dividend of ¥45.00 per...

Analiz Makalesi • Nov 27

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) will pay a dividend of ¥45.00 on the 26th of May. Based on this...

Analiz Makalesi • Nov 08

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will pay a dividend of ¥45.00 per...

Analiz Makalesi • Nov 04

We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Analiz Makalesi • Oct 17

Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations

Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) healthy profit numbers didn't contain any surprises for investors. We...

Analiz Makalesi • Sep 16

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing

When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 13x, you may consider...

Analiz Makalesi • Aug 20

Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) dividend will be increasing from last year's payment of the same...

Analiz Makalesi • Jul 26

Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be paying its dividend of...

Analiz Makalesi • Jul 11

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its dividend from last year's...

Analiz Makalesi • Jun 27

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its dividend from last year's...

Analiz Makalesi • Jun 13

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its dividend from last year's...

Analiz Makalesi • Apr 09

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

With a price-to-earnings (or "P/E") ratio of 20.9x Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) may be sending...

Analiz Makalesi • Mar 18

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Kazanç ve Gelir Büyüme Tahminleri

TSE:4530 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (JPY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
2/28/2029	176,797	13,067	N/A	16,324	1
2/29/2028	167,285	12,014	4,281	14,904	1
2/28/2027	159,685	11,973	5,665	16,289	1
2/28/2026	163,024	19,160	9,428	17,478	N/A
11/30/2025	159,267	19,988	N/A	N/A	N/A
8/31/2025	155,493	19,682	8,355	16,556	N/A
5/31/2025	154,861	19,534	N/A	N/A	N/A
2/28/2025	156,006	21,758	4,991	18,765	N/A
11/30/2024	150,132	15,537	N/A	N/A	N/A
8/31/2024	150,185	14,650	176	18,593	N/A
5/31/2024	145,420	14,708	N/A	N/A	N/A
2/29/2024	141,706	13,969	5,152	18,188	N/A
11/30/2023	139,276	14,330	N/A	N/A	N/A
8/31/2023	135,688	13,655	2,186	12,416	N/A
5/31/2023	134,033	14,160	N/A	N/A	N/A
2/28/2023	128,330	11,742	4,819	12,727	N/A
11/30/2022	125,411	12,962	N/A	N/A	N/A
8/31/2022	121,261	11,160	8,832	12,698	N/A
5/31/2022	118,825	8,927	N/A	N/A	N/A
2/28/2022	120,193	9,658	15,006	19,199	N/A
11/30/2021	120,351	9,746	N/A	N/A	N/A
8/31/2021	120,135	10,559	12,153	15,796	N/A
5/31/2021	117,389	11,499	N/A	N/A	N/A
2/28/2021	114,510	9,250	1,901	5,289	N/A
11/30/2020	122,736	8,996	N/A	N/A	N/A
8/31/2020	130,517	14,839	19,468	23,638	N/A
5/31/2020	136,641	16,894	N/A	N/A	N/A
2/29/2020	140,992	18,694	23,669	27,395	N/A
11/30/2019	139,912	21,295	N/A	N/A	N/A
8/31/2019	137,425	17,594	N/A	16,497	N/A
5/31/2019	139,142	17,665	N/A	N/A	N/A
2/28/2019	143,408	19,204	N/A	15,772	N/A
11/30/2018	140,891	16,608	N/A	N/A	N/A
8/31/2018	143,791	18,891	N/A	21,587	N/A
5/31/2018	145,288	18,897	N/A	N/A	N/A
2/28/2018	147,870	19,119	N/A	30,453	N/A
11/30/2017	145,749	17,895	N/A	N/A	N/A
8/31/2017	144,941	20,495	N/A	25,077	N/A
5/31/2017	143,853	19,540	N/A	N/A	N/A
2/28/2017	145,925	20,395	N/A	19,910	N/A
11/30/2016	149,298	20,806	N/A	N/A	N/A
8/31/2016	153,871	17,694	N/A	27,819	N/A
5/31/2016	160,325	18,778	N/A	N/A	N/A
2/29/2016	161,852	17,784	N/A	30,923	N/A
11/30/2015	164,086	19,626	N/A	N/A	N/A
8/31/2015	162,119	18,586	N/A	25,757	N/A
5/31/2015	158,667	18,321	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 4530 şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -1.7% ).

Kazançlar ve Piyasa: 4530 şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -1.7% ).

Yüksek Büyüme Kazançları: 4530 şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor.

Gelir ve Pazar: 4530 şirketinin gelirinin (yıllık 4% ) JP pazarından (yıllık 6.1% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 4530 şirketinin gelirinin (yıllık 4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 4530 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 4.9 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/14 23:16
Gün Sonu Hisse Fiyatı	2026/05/08 00:00
Kazançlar	2026/02/28
Yıllık Kazançlar	2026/02/28

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Hisamitsu Pharmaceutical Co., Inc. 9 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Ritsuo Watanabe	BofA Global Research
Hidemaru Yamaguchi	Citigroup Inc
Akitada Iwasa	Daiwa Securities Co. Ltd.

This company listing is no longer active

Hisamitsu Pharmaceutical Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 10% to JP¥4,350

Consensus EPS estimates increase by 23%

Price target increased by 7.8% to JP¥4,850

Consensus EPS estimates increase by 12%

Price target increased by 8.0% to JP¥4,700

Price target decreased by 15% to JP¥4,250

Recent updates

Hisamitsu Pharmaceutical Co., Inc.(TSE:4530) dropped from FTSE All-World Index (USD)

Full year 2026 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 28, 2026

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2026 Results on Apr 13, 2026

New major risk - Revenue and earnings growth

Taiyo Kosan Co., Ltd. completed the acquisition of additional 59.38% stake in Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) from Takasago International Corporation (TSE:4914), Yomeishu Seizo Co.,Ltd. (TSE:2540), The Bank of Saga Ltd. (TSE:8395) and others for approximately ¥250 billion.

Third quarter 2026 earnings released: EPS: JP¥69.15 (vs JP¥62.32 in 3Q 2025)

Hisamitsu Pharmaceutical Co., Inc. Revises Dividend Guidance for the Fiscal Year Ending February 28, 2026

New minor risk - Share price stability

Taiyo Kosan Co., Ltd. agreed to acquire a %97.49 stake in Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) in a management buyout transaction for approximately ¥380.6 billion.

What Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) 25% Share Price Gain Is Not Telling You

Investor sentiment improves as stock rises 18%

These 4 Measures Indicate That Hisamitsu Pharmaceutical (TSE:4530) Is Using Debt Safely

Does Hisamitsu Pharmaceutical (TSE:4530) Deserve A Spot On Your Watchlist?

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥60.00

First half dividend of JP¥60.00 announced

Hisamitsu Pharmaceutical's (TSE:4530) Earnings Are Of Questionable Quality

Second quarter 2026 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of JP¥60.00 per share

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Price target decreased by 10% to JP¥4,350

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 3,000,000 shares, representing 4.09% for ¥15,000 million.

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Final dividend increased to JP¥60.00

Consensus EPS estimates increase by 23%

Price target increased by 7.8% to JP¥4,850

We Think That There Are Issues Underlying Hisamitsu Pharmaceutical's (TSE:4530) Earnings

Hisamitsu Pharmaceutical Co., Inc. Announces Exiting of Sugiyama, Kosuke as Director

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 22, 2025

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2026 Results on Oct 09, 2025

With EPS Growth And More, Hisamitsu Pharmaceutical (TSE:4530) Makes An Interesting Case

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2025 Results on Apr 10, 2025

Upcoming dividend of JP¥45.00 per share

Does Hisamitsu Pharmaceutical (TSE:4530) Have A Healthy Balance Sheet?

Consensus EPS estimates increase by 12%

Price target increased by 8.0% to JP¥4,700

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be ¥45.00

Third quarter 2025 earnings released: EPS: JP¥62.32 (vs JP¥48.25 in 3Q 2024)

Hisamitsu Pharmaceutical Co., Inc. Announces Commemorative Dividend for the Fiscal Year Ending February 28, 2025

Hisamitsu Pharmaceutical (TSE:4530) Is Due To Pay A Dividend Of ¥45.00

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2025 Results on Jan 09, 2025

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

First half dividend of JP¥45.00 announced

We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt

Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing

Upcoming dividend of JP¥45.00 per share

Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2025 Results on Oct 10, 2024

Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. Provides Commemorative Dividend for the Fiscal Year Ending February 28, 2025

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Final dividend of JP¥45.00 announced

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2025 Results on Jul 11, 2024

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,400,000 shares, representing 3.17% for ¥8,901.6 million.

Full year 2024 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2024 Results on Apr 11, 2024